Agency Business briefs

Share this article:
Allergan named Pacific Communications agency of record for the chronic migraine indication on its Botox therapy. The agency, which originated as Allergan's in-house advertising shop and has since been spun off, will handle strategic development, branded and unbranded patient and professional communications, sales tools and field training, key opinion leader activities, Web site development and event management for the indication.

North Shore-LIJ Health System named GCI Health as its PR agency of record. The company operates 15 hospitals in New York City and Long Island.

Spectrum rehired Lissette Capati as VP. Capati returns to the agency from Zeno Group, where she led corporate and scientific communications and social media campaigns for clients in the company's health care practice.

GCI Health named Elisia Canna director of consumer health, reporting to CEO Wendy Lund. Canna joins GCI from Porter Novelli, where she was EVP deputy general manager of the New York health practice and led the launches of Nicorette, NicoDerm CQ and Commit Lozenge, along with the Great American Smokeout.

Biogen Idec hired Conshohocken, PA-based Diccicco Battista Communications to build a patient advocacy program combining traditional, digital and grassroots components and to handle brand communications promoting the company's development of MS therapies.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?